CHICAGO -- Sacubitril/valsartan (Entresto) was effective at keeping cardiotoxicity at bay in high-risk people receiving anthracycline chemotherapy in the SARAH trial. Cancer patients were less likely ...

Sacubitril-valsartan, a common drug combination for heart failure, cuts the risk for cardiomyopathy after chemotherapy in patients who received anthracycline drugs by 77% in the first randomized ...

About The Study: In this post hoc pooled analysis of 13,194 patients with chronic heart failure (HF) in the PARADIGM-HF and PARAGON-HF randomized clinical trials, sacubitril/valsartan significantly ...

Sacubitril/valsartan significantly reduces NT-proBNP levels in patients with heart failure with reduced ejection fraction (HFrEF) over 3 years, with no significant changes in sST2 and galectin-3.

In the PANORAMA-HF trial, children receiving sacubitril/valsartan for their heart failure experienced clinically meaningful improvements similar to those seen in children receiving enalapril, although ...

"In conclusion, adjuvant treatment for early breast cancer is associated with a reduction in left ventricular ejection fraction that was not significantly attenuated by sacubitril-valsartan," the ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using SACUBITRIL/VALSARTAN ALPHAPHARM?

Please provide your email address to receive an email when new articles are posted on . The cost-effectiveness of sacubitril/valsartan was intermediate in patients with HF with mildly reduced EF. The ...

The fixed-dose combination of sacubitril and valsartan (trade name: Entresto) has been approved since November 2015 for adults with symptomatic chronic heart failure with reduced pump function. In its ...